Ipsen appoints Karen Witts as new independent member of the Board of Directors | Nation/World


PARIS–(BUSINESS WIRE)–January 21, 2022–

Regulatory news:

This press release is multimedia. View the full press release here: https://www.businesswire.com/news/home/20220120006035/en/

Karen Witts (Photo: Business Wire)

Ipsen (Euronext: IPN; ADR: IPSEY) today announces the appointment of Karen Witts to its Board of Directors as an independent member.

Karen Witts was Group Chief Financial Officer of Compass Group Plc until October 2021. Compass is the world’s leading restaurant operator, operating in 43 countries and employing over 500,000 people. She was responsible for corporate strategy and planning, business performance management and reporting, financial reporting and control, tax and treasury activities, mergers and acquisitions, internal audit and enterprise risk management, investor relations, and led the digital and technology function.

Prior to this, Karen was Group Finance Director at Kingfisher Plc, the international home improvement company. She has also held various senior positions in strategic finance in companies such as Vodafone Group Services Ltd and BT Plc. She brings her expertise in transformation, investment and risk management. Karen is an experienced non-executive director and audit chair.

She is a Fellow of the Institute of Chartered Accountants of England and Wales and holds an MA from the University of Edinburgh.

Following this cooptation, the Board of Directors is made up of fourteen directors (six women

and eight men) including four independent directors and two directors representing employees.

The General Assembly to be held in 2022 will be called upon to ratify this decision for the remainder of the term of her outgoing predecessor (Carol Stuckley), expiring at the General Assembly in 2025.

Representing more than 40%, directors representing employees not being taken into account in this calculation, pursuant to Article L.225-18-1 of the French Commercial Code.

Ipsen

Ipsen is a mid-market international biopharmaceutical company specializing in transformative medicines in oncology, rare diseases and neurosciences; it also has a well-established Consumer Healthcare business. With total sales of more than €2.5 billion in fiscal year 2020, Ipsen markets more than 20 medicines in more than 115 countries, with a direct commercial presence in more than 30 countries. The Company’s research and development efforts focus on its innovative and differentiating technological platforms located at the heart of major biotechnology and life sciences hubs: Paris-Saclay, France; Oxford, UK; Cambridge, USA; Shanghai, China. Ipsen has approximately 5,700 employees worldwide and is listed in Paris (Euronext: IPN) and in the United States via a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

Forward-looking statements

The forward-looking statements, objectives and targets contained herein are based on Ipsen’s current management strategy, beliefs and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial objectives, which have been set assuming reasonable macroeconomic conditions based on information available today. The use of the words “believes”, “anticipates” and “expects” and similar expressions is intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and rulings. . Furthermore, the objectives described in this document were established without taking into account assumptions of external growth and possible future acquisitions, which could modify these parameters. These objectives are based on data and assumptions considered reasonable by Ipsen. These objectives depend on conditions or facts likely to occur in the future, and not exclusively on historical data. Actual results could differ materially from these objectives given the occurrence of certain risks and uncertainties, including the fact that a promising product in the early development or clinical trial phase may never be brought to market. or achieve its business objectives, including for regulatory or competitive reasons. Ipsen must or could face competition from generic products which could result in a loss of market share. Furthermore, the Research and Development process involves several stages, each of which carries a substantial risk that Ipsen will not be able to achieve its objectives and will be forced to abandon its efforts on a product in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained in preclinical trials will be confirmed later in clinical trials, nor that the results of clinical trials will be sufficient to demonstrate the safety and efficacy of the product concerned. There can be no guarantee that a product will receive the necessary regulatory approvals or that the product will prove to be a commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward health care cost containment; technological advances, new products and patents obtained by competitors; challenges inherent in developing new products, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative products; and exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could engage in behavior that could harm Ipsen’s business and financial results. Ipsen cannot be certain that its partners will fulfill their obligations. He might not be able to get any benefit from these deals. Failure of one of Ipsen’s partners could generate revenues below expectations. Such situations could have a negative impact on Ipsen’s business, financial situation or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, objectives or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which such statements are based, except if required by law. Ipsen’s business is subject to the risk factors described in its reference documents filed with the Autorité des Marchés Financiers. The risks and uncertainties presented are not exhaustive and the reader is invited to refer to Ipsen’s 2020 Universal Registration Document, available on ipsen.com.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220120006035/en/

CONTACT: Media

Gwenan White

Executive Vice President, Communications and Public Affairs

+44 7876 391 429Fanny Allaire

Director of Global Communications

+33 6 08 91 92 55Investors

Craig Brands

Vice President, Investor Relations

+44 7584 349 193Adrien Dupin de Saint-Cyr

Investor Relations Manager

+33 6 64 26 17 49

KEYWORD: FRANCE EUROPE

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Ipsen

Copyright BusinessWire 2022.

PUBLISHED: 01/21/2022 01:00 AM/DISC: 01/21/2022 01:02 AM

http://www.businesswire.com/news/home/20220120006035/en Copyright Business Wire 2022.

Previous F&B industry players meet with Karnataka CM and demand relaxation of COVID restrictions - The New Indian Express
Next Faisal Akram: Texas synagogue hostage taker twice referred to government counter-extremism program